Phaseline

Companies › Biocity Biopharmaceutics

Biocity Biopharmaceutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SC0062–Phase 3IgA Nephropathy (IgAN)Dec 2026
BC3195
anti-CDH3 antibody-drug conjugate with MMAE payload
CDH3Phase 1Advanced Cancer; Locally Advanced or Metastatic Solid TumorsApr 2027
BC2027 for Injection–Phase 1Advanced Solid MalignanciesDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06819826SC0062Phase 3IgA Nephropathy (IgAN)GenitourinaryDec 2026
NCT06548672BC3195Phase 1Advanced CancerOncologyApr 2027
NCT07368478BC2027 for InjectionPhase 1Advanced Solid MalignanciesOncologyDec 2027
NCT07469774BC3195Phase 1Locally Advanced or Metastatic Solid TumorsOncologyDec 2027

Targets

CDH3 (1)

Companies with the same targets

–

Companies built like this

Day One Biopharmaceuticals Nuvalent RayzeBio BioRay Pharmaceutical Stemline Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.